We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
F-FDG and Other Labeled Glucose Derivatives for Use in Radionuclide Diagnosis of Oncological Diseases (Review).
- Authors
Petriev, V.; Tishchenko, V.; Krasikova, R.
- Abstract
This review addresses progress in the radionuclide diagnosis of oncological diseases using radiopharmaceutical preparations (RPP) based on labeled glucose derivatives. Most attention is paid to 2-[F]fluoro-2-deoxy-D-glucose (F-FDG), a glucose analog labeled with fluorine-18 ( T = 110 min) and the only radiotracer for glycolysis, which is used in 90% of clinical studies using positron emission tomography (PET). We describe approaches to the synthesis of F-FDG and state-of-the-art automated technologies allowing tens of clinical doses of RPP for PET investigations of patients to be prepared. The main areas of use of PET with F-FDG in the diagnosis of various tumors are discussed, as is the potential for using glucose derivatives with other radionuclides (Ga, I, Tc, Re) as tracers for use in PET and SPECT diagnosis.
- Subjects
FLUORODEOXYGLUCOSE F18; GLUCOSE derivatives; RADIONUCLIDE imaging; CANCER diagnosis; RADIOPHARMACEUTICALS; RADIOACTIVE tracers in biology
- Publication
Pharmaceutical Chemistry Journal, 2016, Vol 50, Issue 4, p209
- ISSN
0091-150X
- Publication type
Article
- DOI
10.1007/s11094-016-1425-y